How is atezolizumab (Tecentriq) administered?

Atezolizumab is a cancer treatment given as either a slow intravenous (IV) infusion (Tecentriq) or as a subcutaneous (under the skin) injection (Tecentriq Hybreza). These products have different recommended dosage and administration instructions but are both administered by healthcare providers and are approved for the same uses.

Atezolizumab (brand name: Tecentriq) is given by a slow intravenous (IV) infusion into your vein, usually once every 2, 3 or 4 weeks. Your initial infusion may last 60 minutes, and infusion times after this may be reduced to 30 minutes, based on your tolerability. A health care provider will give you this infusion, often in a clinic setting.

Atezolizumab and hyaluronidase-tqjs (brand name: Tecentriq Hybreza) was approved in Sept. 2024 as a subcutaneous injection form of atezolizumab. The subcutaneous injection is given in the thigh area under the skin.

• If you are eligible for this treatment, it can lower administration time to about 7 minutes, instead of the 30-60 minutes that is needed for Tecentriq IV infusion. Tecentriq Hybreza is normally given once very 3 weeks.
• Addition of the enzyme hyaluronidase helps to create channels in the tissue and improve the absorption of atezolizumab during subcutaneous administration.

Your doctor will determine how long to treat you with atezolizumab. You will typically keep using this medicine until your disease worsens or you have side effects that require you to stop treatment.

You may be given other medications as part of your treatment regimen, either given at the clinic or to take at home. Take these medicines exactly as prescribed by your doctor.

How is atezolizumab (Tecentriq) used in cancer?

Atezolizumab and atezolizumab and hyaluronidase-tqjs are approved to treat several different types of cancer in adults. It’s effectiveness and your length of response will depend upon your diagnosis, previous treatments, and other medical conditions, among other factors. Cancer treatment is always individualized for each patient.

Atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) are used to treat:

• advanced melanoma (skin cancer)
• metastatic non-small cell lung cancer (NSCLC)
• extensive-stage small cell lung cancer (SCLC)
• liver cancer (hepatocellular carcinoma)
• alveolar soft part sarcoma (ASPS), a rare soft tissue tumor.

In December 2022, Genentech voluntarily withdrew the U.S. accelerated approval for Tecentriq in locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) in patients who are not eligible for cisplatin-containing chemotherapy. Results from the IMvigor130 study did not meet the endpoint of overall survival (OS) for Tecentriq plus chemotherapy compared with chemotherapy alone.

In August 2021, Genentech voluntarily withdrew the U.S. accelerated approval for Tecentriq in combination with albumin-bound paclitaxel for adults with triple-negative breast cancer (mTNBC). This is not related to any changes in either the effectiveness or safety associated with Tecentriq.

In March 2021, Genentech voluntarily withdrew the U.S. accelerated approval for Tecentriq in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer). Other bladder cancer uses were not affected. Results from study IMvigor211 did not meet its primary endpoint of overall survival in the PD-L1 high patient population.

Related questions

• Are there cost-saving programs for Tecentriq?
• How effective is atezolizumab (Tecentriq)?
• Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?

Learn More

For detailed dosage information, see:

• atezolizumab (Tecentriq) dosage
• atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) dosage

Bottom Line

Atezolizumab (Tecentriq) is given by a slow intravenous (IV) infusion into your vein, usually once every 2, 3 or 4 weeks. A health care provider will give you this infusion, often in a clinic setting.

• Your initial infusion typically lasts for 60 minutes, and infusions after this may be reduced to 30 minutes, based on how well you tolerate the medicine.
• Your time at the clinic will usually be longer than this, due to preparation beforehand and needed observation after the infusion. Ask your health care provider how long you can expect to be at the clinic.

Atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) is given as a subcutaneous (under the skin) injection in your thigh area, and it takes about 7 minutes. It is typically given once every 3 weeks.

Atezolizumab (Tecentriq) and Atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) are both manufactured by Genentech.

This is not all the information you need to know about atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for safe and effective use. Review the full Tecentriq information and discuss this information with your doctor or other health care provider.

Read next

See also:

Related medical questions

• Pembrolizumab vs. nivolumab: How do they compare?
• How long does it take for Lenvima to work?
• How long do you take Lenvima?
• Can you drink alcohol while taking Mavyret?
• How does Nexavar work? Is it a chemo drug?
• What is the success rate of Cabometyx (cabozantinib)?
• How effective are Opdivo and Yervoy when taken together?
• How effective is Nexavar? Does it shrink tumors?
• Opdivo vs Opdivo Qvantig: What is the Difference?
• What type of drug is Lenvima? Is it a chemo drug?
• How effective is Lenvima?
• Does Cabometyx (cabozantinib) cure cancer?
• Lenvatinib vs sorafenib: for first line treatment in HCC?
• Is Nexavar cost covered by Medicare?
• What is the difference between Cabometyx and Cometriq?

Drug information

• Atezolizumab (6 reviews)
• Tecentriq (1 reviews)
• Tecentriq Hybreza

Related support groups

• Atezolizumab (6 questions, 4 members)
• Tecentriq (6 questions, 5 members)
• Tecentriq Hybreza (1 questions, 3 members)
• Hepatocellular Carcinoma (23 questions, 23 members)
• Non-Small Cell Lung Cancer (53 questions, 73 members)
• Melanoma (20 questions, 52 members)
• Small Cell Lung Cancer (10 questions, 20 members)
• Alveolar Soft Part Sarcoma (5 questions, 3 members)

Medical Disclaimer